Neuland Laboratories Limited.
NEULANDLAB · ISIN: INE794A01010
Neuland Laboratories Limited. is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE794A01010.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 500 TRI (0.10%), NIFTY SC 250 TRI (0.84%)
CHART
Neuland Laboratories Limited. - growth of ₹100
Growth of ₹100 invested on 2025-10-31, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-9.7%
3M
+1.24%
6M
+28.51%
1Y
+19.84%
3Y CAGR
+70.78%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Neuland Laboratories Limited. - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
Corporate Actions
| Ex-Date | Type | Ratio | Details |
|---|---|---|---|
| 2014-08-13 | RIGHTS | 1.000000 | RIGHTS ISSUE 4 : 25 @ PREMIUM RS 194/- PER EQUITY SHARE |
| 2012-03-21 | RIGHTS | 1.000000 | RIGHTS 5:12 @ PREMIUM RS.35/- PER SHARE |
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-10-07 | SHORT_SELL | 300 |
Frequently asked questions
What is Neuland Laboratories Limited.'s 1-year and 3-year return?
Neuland Laboratories Limited.'s 1-year price return is +19.84%. Its 3-year CAGR (annualized return) is +70.78%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Neuland Laboratories Limited.'s latest financial performance?
Neuland Laboratories Limited.'s trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹2,372 Cr, with a TTM profit after tax of ₹498 Cr and an EBITDA margin of 29.33%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹387.97, with a 5-year EPS growth rate of 46.42% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is Neuland Laboratories Limited.'s quality score?
Neuland Laboratories Limited. has a Punji quality score of 63.6 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Neuland Laboratories Limited.'s technical indicators show?
As of 2026-10-29, Neuland Laboratories Limited.'s RSI (14-day) is 35.29 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Neuland Laboratories Limited.?
As of 2026-06-30, Neuland Laboratories Limited.'s shareholding is split across Promoter (32.26%), Public (67.74%). Promoter holding of 32.26% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is Neuland Laboratories Limited. part of any major market index?
Yes - Neuland Laboratories Limited. is a constituent of NIFTY 500 TRI (0.10% weight) and NIFTY SC 250 TRI (0.84% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
Has Neuland Laboratories Limited. seen any recent bulk or block deals?
Yes, as of 2026-10-07 - the most recent recorded deal was a SHORT_SELL on 2026-10-07 for 300 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
What corporate actions has Neuland Laboratories Limited. announced recently?
The most recent corporate action for Neuland Laboratories Limited. is a RIGHTS (1.000000) with an ex-date of 2014-08-13, for: RIGHTS ISSUE 4 : 25 @ PREMIUM RS 194/- PER EQUITY SHARE. The ex-date is the cutoff - only shareholders who held the stock before this date qualify for the action (dividend, split, bonus, or rights issue, depending on type). Corporate actions typically adjust the stock's price and/or share count mechanically on the ex-date, which is why historical price charts are usually shown adjusted for these events.
Stock data · Not financial advice · Past performance does not indicate future returns